How does Resmetirom (selective thyroid‑hormone receptor‑β agonist) work in treating biopsy‑proven NASH with METAVIR stage F2‑F3 in an adult patient with stable liver function, adequate platelets, Child‑Pugh A, and eGFR ≥30 mL/min/1.73 m²?

How Resmetirom Works in NASH with F2-F3 Fibrosis

Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist that works by mimicking thyroid hormone T3 specifically in the liver, where it reduces intrahepatic triglycerides by promoting fatty acid β-oxidation, lipophagy, and mitochondrial biogenesis, while simultaneously improving lipid metabolism and reducing lipotoxic injury that drives steatohepatitis and fibrosis progression. 1

Molecular Mechanism

Resmetirom functions as a partial agonist of THR-β, producing 83.8% of the maximum response compared to natural T3, with an EC50 of 0.21 µM. Critically, it demonstrates liver selectivity through preferential THR-β activation (the predominant thyroid receptor in hepatocytes) while showing only 48.6% efficacy at THR-α (EC50 of 3.74 µM), which mediates thyroid effects in the heart and bone. This selectivity profile minimizes systemic thyroid-related adverse effects. 1

Hepatic Effects in Your Patient Population

In patients with biopsy-proven NASH and METAVIR F2-F3 fibrosis (the exact FDA-approved indication), resmetirom achieves multiple therapeutic actions:

Fat Reduction

• Decreases hepatic steatosis by stimulating increased hepatic fatty acid β-oxidation and promoting lipophagy (autophagy of lipid droplets)
• Reduces liver fat content measurable by MRI-PDFF as early as week 16, with continued improvement through 52 weeks 1
• In the MAESTRO-NASH trial, achieved 32.9% relative reduction in hepatic fat at 12 weeks and 37.3% at 36 weeks compared to placebo 2, 3

Anti-inflammatory and Anti-fibrotic Actions

• Reduces lipotoxicity by decreasing the burden of lipotoxic lipids that drive hepatocyte injury, inflammation, and stellate cell activation
• Promotes mitochondrial biogenesis and mitophagy, improving hepatocellular function
• Achieved NASH resolution (≥2-point reduction in NAFLD activity score) without worsening fibrosis in 25.9-29.9% of patients versus 9.7% with placebo 2
• Improved fibrosis by ≥1 stage without worsening NASH in 24.2-25.9% versus 14.2% with placebo 2

Metabolic Benefits

• Improves lipid profile by promoting hepatic LDL receptor expression and uptake
• Reduced LDL cholesterol by 13.6-16.3% at 24 weeks 2
• Increases sex hormone binding globulin (SHBG) starting at 4 weeks, though clinical significance remains unclear 1

Pharmacokinetics Relevant to Your Patient

For an adult with stable liver function (Child-Pugh A), adequate platelets, and eGFR ≥30 mL/min/1.73 m²:

• Dosing: Weight-based—80 mg daily if <100 kg, 100 mg daily if ≥100 kg 4
• Absorption: Reaches steady state in 3-6 days; Tmax ~4 hours; food decreases Cmax by 33% but only AUC by 11% (not clinically significant) 1
• Metabolism: Primarily via CYP2C8 to MGL-3623 (28-times less potent metabolite) 1
• Elimination: Half-life 4.5 hours; 67% fecal, 24% urinary excretion 1
• Renal function: No dose adjustment needed for eGFR 30-89 mL/min/1.73 m² 1
• Hepatic function: In Child-Pugh A (mild impairment), resmetirom AUC increases only 1.3-fold and Cmax 1.2-fold—no dose adjustment required 1

Clinical Monitoring Framework

The mechanism translates to measurable improvements following this timeline 4:

Week 12 (Safety Assessment):

• Check liver enzymes to exclude hepatotoxicity signal
• Early transient ALT increases may occur (especially with concomitant statins), typically <1.5x baseline, resolving by week 8
• Do not assess efficacy yet—changes at 12 weeks don't reliably predict treatment response

Month 6 (Disease Monitoring):

• ALT and imaging (VCTE or MRI-PDFF) may suggest early response
• Absence of response at 6 months is inadequate to judge treatment failure

Month 12 and Annually (Efficacy Assessment):

• Continue if: ALT improved/normalized OR stable ALT with ≥30% MRI-PDFF reduction OR ≥30% drop in liver stiffness
• Discontinue if: No MRI-PDFF response, >30% increase in liver stiffness, or worsening in ≥2 noninvasive tests 4

Important Caveats

• Thyroid effects: Decreases FT4 (prohormone) starting at week 4 due to hepatic THR-β activation, but this is expected and does not indicate systemic hypothyroidism 1
• Common side effects: Mild-to-moderate diarrhea (median onset 6-17 days, duration 20 days) and nausea (onset 5-28 days, duration 26-28 days) are dose-dependent; led to discontinuation in 8 per 100 person-years at 100 mg 4
• Drug interactions: Moderate CYP2C8 inhibitors (e.g., clopidogrel) increase resmetirom exposure 1.7-fold; resmetirom increases statin levels (rosuvastatin Cmax 2.9-fold, AUC 1.8-fold) 1

The mechanism directly addresses the pathophysiology of NASH—reducing hepatic fat accumulation, decreasing lipotoxic injury, and interrupting the inflammatory-fibrotic cascade—making it the first conditionally approved liver-directed therapy for this population. 4